GLP2-T vs GLP3-R: Dual-Agonist vs Triple-Agonist Research Peptide Comparison
GLP2-T vs GLP3-R: Dual-Agonist vs Triple-Agonist Research Peptide Comparison
Research peptides for laboratory use only. Not approved by the FDA. Not for human consumption. By purchasing, you confirm you are a qualified researcher operating in a controlled laboratory setting.
Overview
GLP-class research peptides are one of the most active categories in current preclinical metabolic research. The category has progressed rapidly from single-agonist to dual-agonist to triple-agonist designs, each generation adding incremental receptor coverage to the prior generation. GLP2-T and GLP3-R sit at the dual-agonist and triple-agonist generations respectively. This guide compares the receptor profiles, the published research framing, the spec-sheet differences, and the Pure Chain Aminos SKUs available in this category.
Receptor Profile Contrast
GLP2-T (Dual Agonist)
GLP2-T research material targets the glucagon-like peptide-1 receptor (GLP-1R) and the glucose-dependent insulinotropic polypeptide receptor (GIPR). The dual-agonist class extends the single GLP-1R activity of earlier-generation research peptides by adding GIPR engagement. In published preclinical work, dual GLP-1R + GIPR engagement is associated with effects on insulin secretion, glucagon dynamics, and energy expenditure markers that exceed the single-receptor profile.
GLP3-R (Triple Agonist)
GLP3-R research material adds glucagon receptor (GCGR) engagement to the GLP-1R + GIPR profile, producing a triple-agonist activity pattern. The addition of GCGR is the mechanistically distinct step. In published preclinical literature, glucagon receptor engagement is associated with effects on hepatic glucose handling and on energy expenditure markers above the dual-agonist baseline.
What Each Receptor Does in Published Preclinical Work
GLP-1R: incretin axis activity. In animal models, agonism is associated with glucose-dependent insulin secretion, gastric emptying modulation, and central pathways implicated in feeding behavior research.
GIPR: the second incretin receptor. In animal models, agonism is associated with insulin secretion potentiation and adipose-tissue effects in concert with GLP-1R engagement.
GCGR: glucagon receptor. In animal models, agonism is associated with hepatic glucose output and with energy expenditure increases. GCGR engagement is the mechanism that distinguishes the triple class from the dual class in published work.
Energy Expenditure Marker Differences
In published preclinical comparisons, dual-agonist research material produces measurable shifts in oxygen consumption and respiratory exchange ratio relative to single-agonist controls. Triple-agonist research material produces further shifts above the dual-agonist baseline, attributed to the GCGR contribution. The magnitude of the additional triple-agonist signal varies by model and dose, and is the active subject of ongoing preclinical investigation.
Half-Life Engineering
Both GLP2-T and GLP3-R are engineered for extended plasma half-life relative to the native incretin hormones, which have half-lives measured in minutes. The structural strategies used in this class include sequence modifications resistant to dipeptidyl peptidase-4 cleavage and fatty-acid conjugation extending albumin binding. The result for research compounding is a research peptide with a multi-day plasma residency in animal models, which simplifies dosing intervals in protocol design.
Side-by-Side Spec Comparison
| Spec | GLP2-T | GLP3-R |
|---|---|---|
| Receptor profile | GLP-1R + GIPR (dual) | GLP-1R + GIPR + GCGR (triple) |
| Generation | Dual agonist | Triple agonist |
| Half-life class | Multi-day in preclinical models | Multi-day in preclinical models |
| PCA vial sizes | 30mg | 10mg (tested at 13.3mg), 20mg |
| Research-context emphasis | Insulin and incretin axis | Insulin, incretin, hepatic glucose, energy expenditure |
Reconstitution Math
GLP2-T 30mg: reconstituted with 3 mL of bacteriostatic water yields 10 mg/mL. A 0.05 mL draw is 500 mcg.
GLP3-R 10mg (tested at 13.3mg): the COA-confirmed mass is 13.3 mg per vial. Reconstituted with 1.33 mL yields 10 mg/mL against the COA mass. With 2 mL, 6.65 mg/mL.
GLP3-R 20mg: reconstituted with 2 mL yields 10 mg/mL.
These figures are arithmetic conversions of label or COA mass to per-volume concentration for research compounding records. They are not protocol guidance.
PCA SKU Mapping
- GLP2-T 30mg — dual-agonist research material
- GLP3-R 10mg tested at 13.3mg — triple-agonist research material with COA-verified mass
- GLP3-R 20mg — larger triple-agonist vial
Documentation Standard
Every GLP-class lot shipped from Pure Chain Aminos carries a per-batch certificate of analysis with HPLC purity verification and mass spectrometry identity confirmation. The GLP3-R 10mg SKU is labeled with the COA-verified mass (13.3mg) rather than nominal mass, because PCA prefers documentation honesty over labeling convention.
Get Started With WELCOME20
New researchers receive 20% off their first qualifying order with code WELCOME20 ($75 minimum). Browse GLP2-T and GLP3-R, or browse the full Pure Chain Aminos catalog.
Research peptides for laboratory use only. Not approved by the FDA. Not for human consumption. By purchasing, you confirm you are a qualified researcher operating in a controlled laboratory setting.
Mechanism Comparison Table
The GLP-2-T (glucagon-like peptide-2 class) and GLP-3-R (glucagon-like peptide-3 receptor class, a triple-agonist class commonly referred to in literature as the GLP-1/GIP/glucagon class) operate at distinct receptor families. The summary table below frames how researchers contrast the two compounds before designing a study.
| Attribute | GLP-2-T | GLP-3-R |
|---|---|---|
| Receptor class focus | GLP-2 receptor (GLP-2R) — enteroendocrine and intestinal epithelium pathway in animal models | Triple-agonist class engaging GLP-1, GIP, and glucagon receptor pathways in animal models |
| Approximate molecular mass | ~3850 Da (33-residue analog) | ~4730 Da (39-residue triagonist analog) |
| Reported half-life (animal model literature) | Extended half-life relative to native GLP-2 due to N-terminal modification; multi-day reservoir reported in some rodent studies | Multi-day half-life reported across triagonist literature; long systemic exposure profile |
| Common research model focus | Intestinal mucosal models, short-bowel research models, GLP-2R pathway probes | Energy-balance models, hepatic-lipid models, multi-receptor agonism research |
| Lyophilization carrier | Bacteriostatic water reconstitution; refrigerated storage | Bacteriostatic water reconstitution; refrigerated storage |
Reconstitution Math Worked Example
Worked example assuming each lyophilized vial is reconstituted with 2 mL of bacteriostatic water. Researchers should always verify against the COA-stated peptide content.
GLP-2-T 30mg vial + 2 mL bac water: 30 mg / 2 mL = 15 mg/mL = 15,000 mcg/mL. A 0.10 mL draw represents 1,500 mcg. A 0.05 mL draw represents 750 mcg. Researchers running titration designs frequently start at smaller fractional volumes to allow finer step increments.
GLP-3-R 20mg vial + 2 mL bac water: 20 mg / 2 mL = 10 mg/mL = 10,000 mcg/mL. A 0.10 mL draw represents 1,000 mcg. The GLP-3-R 10mg SKU tested at 13.3mg reflects an over-fill confirmed by COA — researchers reconstituting that lot should base math on the COA-stated mass, not the label nominal.
The Pure Chain Aminos bacteriostatic water reconstitution guide covers volume selection and aseptic technique step by step.
Stability and Storage Comparison
Both peptides are shipped lyophilized in sealed glass vials and held at 2-8 C until reconstitution. After reconstitution with bacteriostatic water, both are kept refrigerated and most cited research protocols use the reconstituted vial within 30 days. Long-tail compounds in the GLP class are generally reported as stable in solution under cold storage with minimal freeze-thaw cycling. Researchers running multi-week protocols should aliquot working volumes from the master vial rather than warming and re-cooling the whole stock.
Research Literature Snapshot
The selected references below are commonly cited in GLP-2 and triple-agonist class research planning. Citations are provided for literature awareness only and make no efficacy claim.
- Drucker DJ, Yusta B. Physiology and pharmacology of the enteroendocrine hormone glucagon-like peptide-2. Annual Review of Physiology, 2014. PMID: 24161075.
- Jeppesen PB et al. Studies on long-acting GLP-2 analogs in animal short-bowel models. Gastroenterology, 2011 (review series). PMID: 21050846.
- Coskun T et al. LY3437943, a novel triple GIP/GLP-1/glucagon receptor agonist. Molecular Metabolism, 2022. PMID: 35817273.
- Finan B et al. Unimolecular dual incretins maximize metabolic benefits in animal models. Science Translational Medicine, 2013. PMID: 24135798.
- Knerr PJ et al. Triagonist receptor pharmacology in rodent models. Cell Metabolism, 2022 (review series). PMID: 35176017.
Researcher Considerations
GLP-2-T is more frequently selected in research designs centered on intestinal epithelial proliferation, enteroendocrine signaling, or short-bowel rodent models, where engaging GLP-2R is the experimental hypothesis. GLP-3-R class compounds are more frequently selected in designs focused on multi-receptor metabolic agonism, hepatic-lipid models, or comparative energy-balance research, where the triagonist profile is itself the variable under test. Selection should follow the design hypothesis and the published model the laboratory is replicating, not market hype around either receptor class.
FAQ
Are GLP-2-T and GLP-3-R the same class of peptide?
No. GLP-2-T engages the GLP-2 receptor pathway in research models. GLP-3-R is a triagonist research-class compound engaging GLP-1, GIP, and glucagon receptor pathways. They are studied for distinct biological questions.
Why is the GLP-3-R 10mg SKU labeled “tested at 13.3mg”?
The COA for that lot confirms ~13.3 mg of peptide rather than the 10 mg label nominal. Researchers should reconstitute and dose math based on the COA-stated mass, not the label.
How are these peptides typically stored before reconstitution?
Lyophilized vials are stored at 2-8 C, sealed, away from light. After reconstitution with bacteriostatic water, vials are kept refrigerated and most cited research protocols use them within 30 days.
Are these peptides FDA approved?
No. GLP-2-T and GLP-3-R are research-grade reference compounds for laboratory use only and are not FDA approved.
Where can I review published research?
Start with the Pure Chain Aminos GLP-2-T research page and GLP-3 receptor research page for curated PubMed citations.
Why are some GLP-class peptides more expensive than others?
Synthesis difficulty rises sharply with peptide length and modification complexity. Triagonist peptides like the GLP-3-R class involve longer sequences and more demanding purification, which is reflected in COA cost-per-milligram.
Selected SKU Options
Pure Chain Aminos research-grade SKUs in this category include GLP-2-T 30mg, GLP-3-R 10mg (tested at 13.3mg), and GLP-3-R 20mg. For more on vendor selection, see how to evaluate a research peptide vendor.
Compliance reminder: research peptides for laboratory use only. Not for human consumption. Citations support literature awareness, not efficacy claims.
